Antineoplastic Combined Chemotherapy Protocols

"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.

Descriptor ID	D000971
MeSH Number(s)	E02.183.750.500 E02.319.077.500 E02.319.310.037
Concept/Terms	Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Combined Antineoplastic Agents Antineoplastic Agents, Combined Agent, Combined Antineoplastic Agents, Combined Antineoplastic Antineoplastic Agent, Combined Combined Antineoplastic Agent Antineoplastic Combined Chemotherapy Regimens Drug Combinations, Antineoplastic Anticancer Drug Combinations Anticancer Drug Combination Drug Combination, Anticancer Drug Combinations, Anticancer Antineoplastic Drug Combinations Antineoplastic Drug Combination Combinations, Antineoplastic Drug Drug Combination, Antineoplastic Antineoplastic Chemotherapy Protocols Antineoplastic Chemotherapy Protocols Antineoplastic Chemotherapy Protocol Chemotherapy Protocol, Antineoplastic Protocol, Antineoplastic Chemotherapy Protocols, Antineoplastic Chemotherapy Cancer Chemotherapy Protocols Cancer Chemotherapy Protocol Chemotherapy Protocol, Cancer Chemotherapy Protocols, Cancer Protocol, Cancer Chemotherapy Protocols, Cancer Chemotherapy Chemotherapy Protocols, Antineoplastic

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Clinical Protocols [E02.183]
Antineoplastic Protocols [E02.183.750]
Antineoplastic Combined Chemotherapy Protocols [E02.183.750.500]
Drug Therapy [E02.319]
Antineoplastic Protocols [E02.319.077]
Antineoplastic Combined Chemotherapy Protocols [E02.319.077.500]
Drug Therapy, Combination [E02.319.310]
Antineoplastic Combined Chemotherapy Protocols [E02.319.310.037]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Combined Chemotherapy Protocols".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.

Bar chart showing 727 publications over 29 distinct years, with a maximum of 52 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	2	1	3
1996	1	1	2
1997	1	1	2
1998	0	2	2
2000	1	0	1
2001	2	4	6
2002	26	9	35
2003	32	6	38
2004	33	7	40
2005	31	11	42
2006	31	14	45
2007	23	9	32
2008	34	12	46
2009	29	10	39
2010	33	18	51
2011	37	15	52
2012	24	7	31
2013	31	4	35
2014	28	13	41
2015	16	14	30
2016	15	11	26
2017	17	6	23
2018	6	6	12
2019	16	4	20
2020	9	9	18
2021	10	8	18
2022	2	13	15
2023	2	8	10
2024	3	9	12

Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. Eur J Cancer. 2025 Jan; 214:115161.

View in: PubMed
Finan JM, Di Niro R, Park SY, Jeong KJ, Hedberg MD, Smith A, McCarthy GA, Haber AO, Muschler J, Sears RC, Mills GB, Gmeiner WH, Brody JR. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.

View in: PubMed
Principe N, Phung AL, Stevens KLP, Elaskalani O, Wylie B, Tilsed CM, Sheikh F, Orozco Morales ML, Kidman J, Marcq E, Fisher SA, Nowak AK, McDonnell AM, Lesterhuis WJ, Chee J. Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade. J Immunother Cancer. 2024 Sep 28; 12(9).

View in: PubMed
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. The TALAPRO-3 study design: a plain language summary. Future Oncol. 2024; 20(30):2225-2231.

View in: PubMed
Desai V, Tadinada SM, Shaghaghi H, Summer R, Lai JCK, Bhushan A. Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells. Anticancer Res. 2024 Jun; 44(6):2307-2323.

View in: PubMed
Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 06; 22(2 D).

View in: PubMed
Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun; 8:e2300494.

View in: PubMed
Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2024 Aug 10; 42(23):2790-2799.

View in: PubMed
Logothetis CN, Horvat NP, Kurian T, Bello C, Chavez J, Isenalumhe L, Shah B, Sokol L, Saeed H, Pinilla J, Gaballa S. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience. Oncol Res. 2024; 32(6):1031-1036.

View in: PubMed
Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 Jun; 22(3):102090.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement